TY - JOUR
T1 - Does non-invasive prenatal testing affect the livebirth prevalence of Down syndrome in the Netherlands? A population-based register study
AU - de Groot-van der Mooren, Maurike
AU - de Graaf, Gert
AU - Weijerman, Michel E.
AU - Hoffer, Mariette J.V.
AU - Knijnenburg, Jeroen
AU - van der Kevie-Kersemaekers, Anne Marie M.F.
AU - Kooper, Angelique J.A.
AU - Voorhoeve, Els
AU - Sikkema-Raddatz, Birgit
AU - van Zutven, Laura J.C.M.
AU - Srebniak, Malgorzata Ilona
AU - Huijsdens-van Amsterdam, Karin
AU - Engelen, John J.M.
AU - Smeets, Dominique
AU - van Kaam, Anton H.
AU - Cornel, Martina C.
N1 - Funding Information:
The authors would like to thank Lia Knegt, Joanne Verweij and Annemarie de Veld-van Heiningen of the WPDT for the annual reports of 2014?2017, and Pieter van Casteren for his advice in performing a specific part of the statistical analysis.
Publisher Copyright:
© 2021 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.
PY - 2021/9
Y1 - 2021/9
N2 - Objective: To evaluate if non-invasive prenatal testing (NIPT) affects livebirth (LB) prevalence of Down syndrome (DS) in the Netherlands. Method: Data from clinical genetics laboratories and the Working Party on Prenatal Diagnosis and Therapy (2014–2018) and previous published data (1991–2013) were used to assess trends for DS LB prevalence and reduction percentage (the net decrease in DS LBs resulting from selective termination of pregnancies). Statistics Netherlands provided general population data. Results: DS LB prevalence increased from 11.6/10,000 in 1991 to 15.9/10,000 in 2002 (regression coefficient 0.246 [95% CI: 0.105–0.388; p = 0.003]). After 2002, LB prevalence decreased to 11.3/10,000 in 2014 and further to 9.9/10,000 in 2018 (regression coefficient 0.234 (95% CI: −0.338 to −0.131; p < 0.001). The reduction percentage increased from 26% in 1991 to 55.2% in 2018 (regression coefficient 0.012 (95% CI: 0.010–0.013; p < 0.001)). There were no trend changes after introducing NIPT as second-tier (2014) and first-tier test (2017). Conclusions: Introducing NIPT did not change the decreasing trend in DS LB prevalence and increasing trend in reduction percentage. These trends may be caused by a broader development of more prenatal testing that had already started before introducing NIPT.
AB - Objective: To evaluate if non-invasive prenatal testing (NIPT) affects livebirth (LB) prevalence of Down syndrome (DS) in the Netherlands. Method: Data from clinical genetics laboratories and the Working Party on Prenatal Diagnosis and Therapy (2014–2018) and previous published data (1991–2013) were used to assess trends for DS LB prevalence and reduction percentage (the net decrease in DS LBs resulting from selective termination of pregnancies). Statistics Netherlands provided general population data. Results: DS LB prevalence increased from 11.6/10,000 in 1991 to 15.9/10,000 in 2002 (regression coefficient 0.246 [95% CI: 0.105–0.388; p = 0.003]). After 2002, LB prevalence decreased to 11.3/10,000 in 2014 and further to 9.9/10,000 in 2018 (regression coefficient 0.234 (95% CI: −0.338 to −0.131; p < 0.001). The reduction percentage increased from 26% in 1991 to 55.2% in 2018 (regression coefficient 0.012 (95% CI: 0.010–0.013; p < 0.001)). There were no trend changes after introducing NIPT as second-tier (2014) and first-tier test (2017). Conclusions: Introducing NIPT did not change the decreasing trend in DS LB prevalence and increasing trend in reduction percentage. These trends may be caused by a broader development of more prenatal testing that had already started before introducing NIPT.
UR - http://www.scopus.com/inward/record.url?scp=85109092446&partnerID=8YFLogxK
U2 - 10.1002/pd.6003
DO - 10.1002/pd.6003
M3 - Article
C2 - 34176145
AN - SCOPUS:85109092446
SN - 0197-3851
VL - 41
SP - 1351
EP - 1359
JO - Prenatal Diagnosis
JF - Prenatal Diagnosis
IS - 10
ER -